Emerging biotech leader AKESF develops Ivonescimab & Cadonilimab; while offering growth potential with US partnerships, ...

Lung cancer (LC) is a major global health issue, with high mortality rates and limited therapeutic options. It is primarily categorized into non-small cell lung cancer (NSCLC) and small cell lung ...

The first patient with small cell lung cancer has been dosed in a phase 1/2 trial investigating first-line iadademstat plus ...

Mesothelioma and lung cancer are different conditions that can be caused by asbestos. Learn more about mesothelioma vs. lung ...

Tarlatamab is a bispecific T-cell engager that binds to DLL3 expressed on the surface of tumor cells and CD3 expressed on the surface of T-cells.

A subset of patients with non-small cell lung cancer (NSCLC) who discontinued immune checkpoint inhibitor (ICI) therapy due ...

A subset of patients with non-small cell lung cancer (NSCLC) who discontinued immune checkpoint inhibitor (ICI) therapy due to ...

An experimental drug now in clinical trials as a cancer treatment could help boost the power of first-line tuberculosis (TB) ...

ALTON The statistics surrounding the incidence rate of lung cancer nationally, state-wide, and locally can literally take your breath away.According to ...

In the Phase III DeLLphi-304 trial, patients with small cell lung cancer administered Imdelltra achieved a statistically ...

Most patients who enroll in the Lung-MAP precision medicine trial in non-small cell lung cancer can now be matched to a targeted investigational treatment based on the results of their prior genomic ...

A new study published in The Annals of Thoracic Surgery suggests that Medicaid expansion under the Affordable Care Act has ...